Larimar Therapeutics, Inc. (LRMR)Healthcare | Biotechnology | Bala Cynwyd, United States | NasdaqGM
4.01 USD
-0.04
(-0.988%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.09 +0.08 (1.995%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:23 a.m. EDT
The long-term investment case is severely compromised by a brutal multi-year decline; the stock has lost nearly 90% of its value over the last nine years, with the most recent annual performance showing a sharp contraction. While the company is advancing a late-stage drug candidate and received a strong buy recommendation from analysts, the market has clearly priced in a lack of sustainable growth, evidenced by negative earnings, negative free cash flow, and a massive gap between the current price and the average analyst target. This disconnect suggests the current valuation reflects a deep skepticism about the commercial viability of the pipeline rather than a simple margin of safety. On the short end, the recent price action shows some resilience, trading slightly above its 50-day moving average, but the heavy options positioning for volatility indicates traders are waiting for a binary catalyst to resolve the uncertainty. With no dividend to provide income and a precarious cash runway highlighted in recent news, the risk-reward profile remains skewed toward caution despite the optimistic analyst consensus. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.131995 |
| AutoETS | 0.137764 |
| AutoARIMA | 0.137766 |
| AutoTheta | 0.302858 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 5.14 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.616 |
| Excess Kurtosis | -0.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.891 |
| Market Cap | 416,570,592 |
| Forward P/E | -3.78 |
| Beta | 0.75 |
| Website | https://www.larimartx.com |
As of Aug. 22, 2026, 3:23 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional breakout. Call volume is heavily skewed toward out-of-the-money strikes (Nov '26, Jan '27), suggesting bets on a sharp rally, while put volume concentrates deeply in-the-money (Dec '26, Jan '27), indicating a hedge against a drop to lower levels. The implied volatility surface shows elevated premiums for deep OTM calls and ITM puts, reflecting a binary event-driven outlook typical of biotech catalysts.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.08086252 |
| Address1 | Three Bala Plaza East |
| Address2 | Suite 506 |
| All Time High | 664.32 |
| All Time Low | 1.53 |
| Ask | 5.29 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 888,420 |
| Average Daily Volume3 Month | 1,945,279 |
| Average Volume | 1,945,279 |
| Average Volume10Days | 888,420 |
| Beta | 0.75 |
| Bid | 2.95 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 1.22 |
| City | Bala Cynwyd |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.01 |
| Current Ratio | 4.703 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.08 |
| Day Low | 3.98 |
| Debt To Equity | 3.891 |
| Display Name | Larimar Therapeutics |
| Dividend Date | 1,590,710,400 |
| Earnings Timestamp | 1,785,846,600 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -178,684,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.496 |
| Enterprise Value | 267,265,584 |
| Eps Current Year | -1.35119 |
| Eps Forward | -1.06036 |
| Eps Trailing Twelve Months | -1.99 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.8768 |
| Fifty Day Average Change | 0.13320017 |
| Fifty Day Average Change Percent | 0.034358278 |
| Fifty Two Week Change Percent | 8.086252 |
| Fifty Two Week High | 6.42 |
| Fifty Two Week High Change | -2.4099998 |
| Fifty Two Week High Change Percent | -0.37538937 |
| Fifty Two Week Low | 2.715 |
| Fifty Two Week Low Change | 1.2950003 |
| Fifty Two Week Low Change Percent | 0.47697988 |
| Fifty Two Week Range | 2.715 - 6.42 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,403,184,600,000 |
| Float Shares | 57,897,040 |
| Forward Eps | -1.06036 |
| Forward P E | -3.781735 |
| Free Cashflow | -94,177,248 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 71 |
| Fullday Change | -0.04 |
| Fullday Change Percent | -0.987653 |
| Fullday Price | 4.09 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.011460001 |
| Held Percent Institutions | 0.93411005 |
| Implied Shares Outstanding | 103,882,937 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania. |
| Long Name | Larimar Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 416,570,592 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_572350487 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -172,604,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 419,687,065 |
| Number Of Analyst Opinions | 10 |
| Open | 4.03 |
| Operating Cashflow | -155,924,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 844 511 9056 |
| Post Market Change | 0.07999992 |
| Post Market Change Percent | 1.9950105 |
| Post Market Price | 4.09 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 4.05 |
| Price Eps Current Year | -2.9677546 |
| Price Hint | 4 |
| Price To Book | 3.2868853 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.582 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.04 |
| Regular Market Change Percent | -0.987653 |
| Regular Market Day High | 4.08 |
| Regular Market Day Low | 3.98 |
| Regular Market Day Range | 3.98 - 4.08 |
| Regular Market Open | 4.03 |
| Regular Market Previous Close | 4.05 |
| Regular Market Price | 4.01 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 641,480 |
| Return On Assets | -0.70961 |
| Return On Equity | -1.39628 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 103,882,937 |
| Shares Percent Shares Out | 0.1294 |
| Shares Short | 13,443,456 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 11,303,953 |
| Short Name | Larimar Therapeutics, Inc. |
| Short Percent Of Float | 0.1999 |
| Short Ratio | 10.43 |
| Source Interval | 15 |
| State | PA |
| Symbol | LRMR |
| Target High Price | 26.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 14.3 |
| Target Median Price | 12.5 |
| Total Cash | 156,267,008 |
| Total Cash Per Share | 1.497 |
| Total Debt | 4,956,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.99 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.921375 |
| Two Hundred Day Average Change | 0.08862519 |
| Two Hundred Day Average Change Percent | 0.022600539 |
| Type Disp | Equity |
| Volume | 641,480 |
| Website | https://www.larimartx.com |
| Zip | 19,004 |